Close

Medicines' (MDCO) Angiomax Win vs Mylan Helps but Hospira Overhang Remains, Says RBC

October 28, 2014 10:52 AM EDT Send to a Friend
RBC Capital maintained an Outperform rating on The Medicines Company (NASDAQ: MDCO) with a price target of $37. Comments follow ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login